Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
暂无分享,去创建一个
J. Corbeil | D. Richman | D. Havlir | S. Spector | C. Ignacio | D. Looney | K. Barringer | D D Richman | J Corbeil | J. Sullivan | J. Sullivan | J Sullivan | C Ignacio | D Havlir | S A Spector | D Looney | S Cheeseman | K Barringer | D Pauletti | D. Havlir | S. Cheeseman | D. Pauletti | Maureen Myers | Stephen A. Spector | Jacques Corbeil | Sarah H. Cheeseman | John L. Sullivan | David Looney | D. Havlir | D. D. Richman | Kevin Barringer | Dan Pauletti | Cheng-Kon Shih | Johanna Griffin | David J. Looney | Johanna A. Griffin
[1] S. J. Clark,et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.
[2] B. Larder. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors , 1992, Antimicrobial Agents and Chemotherapy.
[3] F. Corpet. Multiple sequence alignment with hierarchical clustering. , 1988, Nucleic acids research.
[4] Roy E. Byington,et al. Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. , 1991, Disease markers.
[5] E A Emini,et al. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. , 1992, The Journal of biological chemistry.
[6] E. De Clercq,et al. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy , 1993, Journal of virology.
[7] J. Balzarini,et al. Treatment ofHumanImmunodeficiency VirusType1 (HIV-1)-Infected Cells withCombinations ofHIV-1-Specific Inhibitors Results ina Different Resistance Pattern Than DoesTreatment withSingle-Drug Therapy , 1993 .
[8] Ashley T. Haase,et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.
[9] D. Ho,et al. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. , 1991, The New England journal of medicine.
[10] D. Richman,et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[11] S D Kemp,et al. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.
[12] J. Coffin,et al. Genetic diversity and evolution of retroviruses. , 1992, Current topics in microbiology and immunology.
[13] S. Broder,et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. , 1993, The Journal of clinical investigation.
[14] D. Richman,et al. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs. , 1993, The Journal of biological chemistry.
[15] M. Hirsch,et al. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro , 1992, Antimicrobial Agents and Chemotherapy.
[16] B. Larder,et al. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Condra,et al. HIV and multidrug resistance , 1993, Nature.
[18] J. Condra,et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors , 1993, Antimicrobial Agents and Chemotherapy.
[19] J L Sullivan,et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans , 1993, Antimicrobial Agents and Chemotherapy.
[20] A. Bacolla,et al. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[21] Michael S. Saag,et al. A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase , 1993 .
[22] D. Richman,et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine , 1991, Antimicrobial Agents and Chemotherapy.
[23] S D Kemp,et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. , 1991, Science.
[24] Anthony S. Fauci,et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease , 1993, Nature.
[25] J. Proudfoot,et al. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. , 1991, Biochemistry.
[26] J. Holland,et al. RNA virus populations as quasispecies. , 1992, Current topics in microbiology and immunology.
[27] Paul Kellam,et al. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro , 1993, Nature.
[28] E A Emini,et al. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors , 1991, Journal of virology.
[29] J. Adams,et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. , 1990, Science.
[30] T. Steitz,et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.
[31] D. Richman,et al. The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker. , 1989, The Journal of infectious diseases.
[32] Florence Corpet,et al. Multiple sequence alignment withhierarchical clustering , 1988 .
[33] I. Chen,et al. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[34] D. Richman,et al. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. , 1994, Journal of acquired immune deficiency syndromes.